Overall, the study showed that the established nomogram, which was based on Ki-67 expression, could effectively predict the efficacy of first-line therapeutic options in NSCLC patients with either wildtype or mutant EGFR. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.